PAX8 expression in POMTs, eMOMCs and ePMCs
| PAX8 mAb | PAX8 pAb | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive/total cases (%) | Staining intensity | p Value | Positive/total cases (%) | Staining intensity | p Value | |||||||
| 0 | 1+ | 2+ | 3+ | 0 | 1+ | 2+ | 3+ | |||||
| POMTs | 25/47 (53.2) | 22 | 12 | 9 | 4 | 0.3852* | 37/47 (78.7) | 10 | 18 | 9 | 10 | 0.7238* |
| MBTs | 14/23 (60.9) | 9 | 6 | 5 | 3 | 19/23 (82.6) | 4 | 8 | 6 | 5 | ||
| POMCs | 11/24 (45.8) | 13 | 6 | 4 | 1 | 18/24 (75.0) | 6 | 10 | 3 | 5 | ||
| FIGO stage | 1† | <0.5392† | ||||||||||
| Ia–Ic | 10/21 (47.6) | 11 | 5 | 4 | 1 | 14/21 (66.7) | 7 | 8 | 3 | 3 | ||
| II–IV | 1/3 (33.3) | 2 | 1 | 0 | 0 | 3/3 (1.0) | 0 | 1 | 0 | 2 | ||
| eMOMCs | 0/18 (0) | 0 | 0 | 0 | 0 | <0.001‡ | 3/18 (16.7) | 15 | 2 | 1 | 0 | <0.001‡ |
| Colorectal | 0/7 (0) | 0 | 0 | 0 | 0 | 2/7 (28.6) | 5 | 1 | 1 | 0 | ||
| Appendiceal | 0/6 (0) | 0 | 0 | 0 | 0 | 0/6 (0) | 6 | 0 | 0 | 0 | ||
| Gastric | 0/4 (0) | 0 | 0 | 0 | 0 | 1/4 (25.0) | 3 | 1 | 0 | 0 | ||
| Pancreatic | 0/1 (0) | 0 | 0 | 0 | 0 | 0/1 (0) | 1 | 0 | 0 | 0 | ||
| ePMCs | 0/70 (0) | 0 | 0 | 0 | 0 | <0.001¶ | 32/70 (45.7) | 38 | 10 | 17 | 5 | <0.01¶ |
| Colorectal | 0/29 (0) | 0 | 0 | 0 | 0 | 12/29 (41.4) | 17 | 4 | 6 | 2 | ||
| Gastric | 0/13 (0) | 0 | 0 | 0 | 0 | 3/13 (23.1) | 10 | 1 | 1 | 1 | ||
| Appendiceal | 0/3 (0) | 0 | 0 | 0 | 0 | 2/3 (66.7) | 1 | 1 | 1 | 0 | ||
| Pancreatic | 0/7 (0) | 0 | 0 | 0 | 0 | 3/7 (42.9) | 4 | 1 | 2 | 0 | ||
| Biliary tract | 0/2 (0) | 0 | 0 | 0 | 0 | 1/2 (50) | 1 | 1 | 0 | 0 | ||
| Mammary | 0/16 (0) | 0 | 0 | 0 | 0 | 11/16 (68.8) | 5 | 2 | 7 | 2 | ||
Staining intensity is graded 0–3. Nuclear staining in >5% of malignant cells was considered positive.
*POMTs (MBTs vs carcinoma), Fisher’s exact test.
†POMCs (FIGO stage Ia–Ic vs FIGO stage II–IV), Fisher’s exact test.
‡POMTs vs eMOMCs, Fisher’s exact test.
§POMTs vs ePMCs, Fisher’s exact test.
eMOMCs, extragenital metastatic mucinous carcinomas involving the ovary; ePMCs, extragenital primary mucinous carcinomas; mAb, monoclonal antibody; MBTs, ovarian mucinous borderline tumours; POMCs, primary ovarian mucinous carcinomas; POMTs, primary ovarian mucinous tumours.